Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 6/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.44 |
| ▸ | MIF | P14174 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL15017827 | 0.89 | PDE5A (0.41) | PDE5APDE4BPDE3AMIFADORA2A | |
| SCHEMBL6489458 | 0.80 | PDE4B (0.58) | PDE5APDE4BPDE3AMIFADORA2A | |
| SCHEMBL5847138 | 0.80 | PDE4B (0.46) | PDE5APDE4BPDE3AMIFADORA2A | |
| SCHEMBL19700226 | 0.79 | EGFR (0.49) | PDE5APDE4BPDE3AMIFADORA2A | |
| SCHEMBL15742623 | 0.79 | PDE5A (0.38) | PDE5APDE4BPDE3AMIFADORA2A | |
| SCHEMBL14809647 | 0.79 | PDE5A (0.41) | PDE5APDE4BPDE3AMIFADORA2A | |
| SCHEMBL13257675 | 0.79 | PDE5A (0.38) | PDE5APDE4BPDE3AMIFADORA2A | |
| SCHEMBL6490723 | 0.79 | PDE5A (0.41) | PDE5APDE4BPDE3AMIFADORA2A | |
| SCHEMBL3319530 | 0.79 | EGFR (0.45) | PDE5APDE4BPDE3AMIFADORA2A | |
| SCHEMBL952642 | 0.79 | PDE5A (0.38) | PDE5APDE4BPDE3AMIFADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023164237-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-11702419-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-07-18 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| EP-3402790-B1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3889154-A1 | HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| CN-107208279-B | Etching solution, replenishment solution, and method for forming copper wiring | MEC股份有限公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-3110818-B1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2019-10-23 | — | — | EP | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070185326-A1 | antiinflammatory agents; antiarthritic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185326-A1 | antiinflammatory agents; antiarthritic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070161653-A1 | Pyrazolo-Pyridine Derivatives As Antiherpes Agents | GUDMUNDSSON KRISTJAN | 2007-07-12 | — | — | US | disclosed |
| US-7199120-B2 | Pyrazolo-pyridine derivatives as antiherpes agents | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
| EP-1373199-A4 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1373199-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | Bristol-Myers Squibb Pharma Company (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002074738-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | PDE5A 754/4885PDE4B 714/4885PDE3A 599/4885 |
| US-20070161653-A1 | Pyrazolo-Pyridine Derivatives As Antiherpes Agents | HRH4, HRH2, HRH1 | PDE5A 1148/4885PDE4B 529/4885PDE3A 863/4885 |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | PDE5A 262/4885PDE4B 2024/4885PDE3A 334/4885 |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GCGR | PDE5A 1082/4885PDE4B 1246/4885PDE3A 733/4885 |
| US-11702419-B2 | Heterocyclic compound and use thereof | GRIN2B, GRIN2A, GRIN2C | PDE5A 2202/4885PDE4B 3150/4885PDE3A 2443/4885 |
| US-20070185326-A1 | antiinflammatory agents; antiarthritic agents | MAPK1, CHUK, MAPK3 | PDE5A 1838/4885PDE4B 3459/4885PDE3A 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.